May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Subretinal Administration of Ribozyme to the Proliferating Cell Nuclear Antigen and 5–fluorouracil in Rat Eyes
Author Affiliations & Notes
  • O.R. Kayikcioglu
    Ophthalmology, UCSD – Jacobs Retina Center – Shiley Eye Center, La Jolla, CA
  • L. Cheng
    Ophthalmology, UCSD – Jacobs Retina Center – Shiley Eye Center, La Jolla, CA
  • I. Kozak
    Ophthalmology, UCSD – Jacobs Retina Center – Shiley Eye Center, La Jolla, CA
  • G. Bergeron–Lynn
    Ophthalmology, UCSD – Jacobs Retina Center – Shiley Eye Center, La Jolla, CA
  • C.T. Schulteis
    Immusol Inc, San Diego, CA
  • F.W. Staal
    Immusol Inc, San Diego, CA
  • N. Paoni
    Immusol Inc, San Diego, CA
  • W.R. Freeman
    Ophthalmology, UCSD – Jacobs Retina Center – Shiley Eye Center, La Jolla, CA
  • Footnotes
    Commercial Relationships  O.R. Kayikcioglu, None; L. Cheng, None; I. Kozak, None; G. Bergeron–Lynn, None; C.T. Schulteis, Immusol Inc, San Diego E; F.W. Staal, Immusol Inc E; N. Paoni, Immusol Inc E; W.R. Freeman, Immusol Inc C.
  • Footnotes
    Support  NIH Grand EY07366(WRF) and Immusol Inc, San Diego
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1427. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      O.R. Kayikcioglu, L. Cheng, I. Kozak, G. Bergeron–Lynn, C.T. Schulteis, F.W. Staal, N. Paoni, W.R. Freeman; Subretinal Administration of Ribozyme to the Proliferating Cell Nuclear Antigen and 5–fluorouracil in Rat Eyes . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1427.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Antiproliferative drugs may be useful in inhibiting processes associated with choroidal neovascularization and thus limiting damage in eyes with age related macular degeneration. We planned to investigate the toxicity profile of subretinal injection of ribozyme to the proliferating cell nuclear antigen (PCNA–Rz) and 5–FU, as well as to establish the highest non–toxic subretinal dose for either agent in rat eyes. Evidence shows that there is a synergistic antiproliferative effect, if a combination of both is injected. Methods: Thirty Brown Norway rats were used. Only one eye of each rat was injected with drug; the fellow eye was injected with BSS as control. PCNA–Rz at 5µg, 50µg, and 500µg in 5µl and 5–FU at 0.3, 1.5, and 7.5µg in 5µl were tested. For all drugs, each dose was tested in 5 eyes. After injection, the eyes were monitored by slit lamp, indirect ophthalmoscope and ERG examinations. Rats were sacrificed at 2 weeks, and the globes were processed for histology. Results: The highest non–toxic dose for subretinal PCNA–Rz was 50µg in 5µl. 500µg in 5µl was toxic at the injection site, showing disturbance of pigmentation at the bleb area and corresponding histological changes of retinal photoreceptor loss and retinal pigment epithelium proliferation and irregularity. Subretinal injection of all three doses of 5–FU did not show any toxicity. Even the highest dose of 7.5µg in 5µl was well tolerated in the subretinal space with normal ERG and histology. Conclusions: Subretinal PCNA–Rz of 50µg in 5µl and 5–FU dose of 7.5µg in 5µl are safe for subretinal injections in rats. Subretinal injection of a combination of the two may be non–toxic and synergistic for inhibiting subretinal proliferation associated with AMD; we are currently evaluating this combination therapy.

Keywords: age-related macular degeneration • choroid: neovascularization • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×